evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,006 questions · 3,171 findings · 607 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 411 · 13%GRADE not reported 153 · 4.8%Very low 968 · 30.5%Low 897 · 28.3%Moderate 589 · 18.6%High 153 · 4.8%

Intervention not reported

All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention may leads to lower all‐cause mortality at day 28 (low certainty).

1 finding from 1 review

Intervention not reported

Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).

1 finding from 1 review

Intervention not reported

Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Admission to hospital or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention may leads to lower admission to hospital or death (low certainty).

1 finding from 1 review

Intervention not reported

Admission to ICU or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Time to symptom resolution · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

SAEs during the study period · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention may leads to lower SAEs during the study period (low certainty).

1 finding from 1 review

Intervention not reported

Any grade TEAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention showed no clear difference in any grade TEAE (moderate certainty).

1 finding from 1 review

Intervention not reported

Any grade TRAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease

The intervention probably leads to higher any grade TRAE (moderate certainty).

1 finding from 1 review